 Connection
Simon Hambidge to Vaccines, Inactivated
This is a "connection" page, showing publications Simon Hambidge has written about Vaccines, Inactivated.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.364 |
|
|
|
-
Narwaney KJ, Glanz JM, Norris JM, Fingerlin TE, Hokanson JE, Rewers M, Hambidge SJ. Association of HLA class II genes with clinical hyporesponsiveness to trivalent inactivated influenza vaccine in children. Vaccine. 2013 Feb 04; 31(7):1123-8.
Score: 0.105
-
Hambidge SJ, Ross C, McClure D, Glanz J. Trivalent inactivated influenza vaccine is not associated with sickle cell hospitalizations in adults from a large cohort. Vaccine. 2011 Oct 26; 29(46):8179-81.
Score: 0.096
-
Glanz JM, Newcomer SR, Hambidge SJ, Daley MF, Narwaney KJ, Xu S, Lee GM, Baggs J, Klein NP, Nordin JD, Naleway AL, Belongia EA, Weintraub ES. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med. 2011 Aug; 165(8):749-55.
Score: 0.095
-
Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K, Jackson L, Mullooly JP, Zangwill KM, Marcy SM, Black SB, Lewis EM, Shinefield HR, Belongia E, Nordin J, Chen RT, Shay DK, Davis RL, DeStefano F. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006 Oct 25; 296(16):1990-7.
Score: 0.068
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|